Path ID: DB06193_MESH_D008228_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C086548 | Pixantrone | Drug |
| UniProt:P11388 | DNA topoisomerase 2-alpha | Protein |
| MESH:D018736 | DNA adducts | ChemicalSubstance |
| GO:0006974 | cellular response to DNA damage stimulus | BiologicalProcess |
| GO:0030263 | apoptotic chromosome condensation | BiologicalProcess |
| GO:0008219 | cell death | BiologicalProcess |
| CL:0001063 | tumor cells | Cell |
| MESH:D008228 | Non-Hodgkin’s lymphoma | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Pixantrone | INCREASES ABUNDANCE OF | Dna Adducts |
| Dna Adducts | DECREASES ACTIVITY OF | Dna Topoisomerase 2-Alpha |
| Dna Topoisomerase 2-Alpha | POSITIVELY REGULATES | Cellular Response To Dna Damage Stimulus |
| Cellular Response To Dna Damage Stimulus | POSITIVELY REGULATES | Apoptotic Chromosome Condensation |
| Apoptotic Chromosome Condensation | POSITIVELY CORRELATED WITH | Cell Death |
| Cell Death | DECREASES ABUNDANCE OF | Tumor Cells |
| Tumor Cells | MANIFESTATION OF | Non-Hodgkin’S Lymphoma |
Comment: pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union.
Reference: